Guided Therapeutics Inc. (GTHP) intrinsic value & 10-year financials
Guided Therapeutics Inc. (GTHP) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 15.4% a year to $767.0K, with an average return on invested capital of 36.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.19
- Market cap
- $14.9M
- Revenue (FY2025)
- $767.0K
- Revenue growth (10-yr CAGR)
- 15.4%
- ROIC (10-yr avg)
- 36.5%
- Free cash flow (FY2025)
- -$1.1M
GTHP 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $767.0K | -$3.2M | -$0.04 | -$1.1M | -309.3% | 44.6% |
| FY2024 | $7.0K | -$2.4M | -$0.05 | -$1.1M | -30114.3% | 44.5% |
| FY2023 | $98.0K | -$3.5M | -$0.07 | -$1.7M | -3527.6% | 75.4% |
| FY2022 | $13.0K | -$4.3M | -$0.15 | -$1.5M | -25638.5% | 63.0% |
| FY2021 | $81.0K | -$2.1M | -$0.18 | -$1.6M | -2916.0% | 29.1% |
| FY2020 | $102.0K | -$279.0K | -$0.00 | -$1.9M | -1031.4% | 7.4% |
| FY2019 | $36.0K | -$1.9M | -$0.00 | -$806.0K | -2602.8% | 6.7% |
| FY2018 | $57.0K | $1.0M | $0.00 | — | -2715.8% | 15.2% |
| FY2017 | $244.0K | -$10.7M | $0.00 | — | -1279.1% | 33.5% |
| FY2016 | $0 | -$4.0M | — | -$1.8M | — | 46.2% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
GUIDED THERAPEUTICS INC revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
GUIDED THERAPEUTICS INC has earned high returns on invested capital, averaging 36.5% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
GUIDED THERAPEUTICS INC has not shown aggressive share repurchases (>10% retirement) or a major balance-sheet leverage increase (>50% net debt growth) over the 10-year window.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, GUIDED THERAPEUTICS INC is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $0.00 per share.